Following a South Korean distribution agreement signed in May, the deal further expands the reach of NanoCellect's microfluidic-based cell handling products.
Using brain samples from individuals with or without multiple sclerosis, researchers detected declining projection neuron levels and related immune cell shifts.
The firm said that the technology contains an enclosed, sterile sorting chip that enables users to type cells according to biomarkers and sort them into separate outputs.
Based on gene expression, researchers identified cell clusters in testes samples from two adult men and two infants, providing clues that may eventually aid fertility treatments.
The researchers hope the datasets from their study can help to explain the effects of disease-associated variants on specific cell types of the immune system.
The Ann Arbor-based biotech startup will use the funding to develop its microbubble technology that allows for removal of biomolecules from biological samples.
